Petmed Express earnings release, June 2, 2026
PetMeds® Announces Fourth Quarter and Fiscal Year 2026 Financial Results
Delray Beach, Florida, June 2, 2026, PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its fourth quarter and fiscal year ended March 31, 2026.
Fourth Quarter Fiscal 2026 Financial Highlights Compared to Prior Year Period
• Net sales of $42.8 million compared to $50.8 million in the prior year period, a decrease of 15.6%, primarily driven by a decline in prescription medication sales.
• Net loss of $4.1 million, or $(0.19) per diluted share, compared to a net loss of $11.6 million, or $(0.56) per diluted share, for the prior year period. The decrease in the net loss can be attributed to lower general and administrative expenses, the absence of the prior-year trade name impairment charge, higher interest income, and a lower provision for income taxes, driven by the Company establishing a full valuation allowance against its net deferred tax asset in the prior year period. These favorable factors were partially offset by lower gross profit resulting from decreased net sales.
• Adjusted EBITDA¹ was $(2.8) million compared to $(1.9) million in the prior year period.
Full Year Fiscal 2026 Financial Highlights Compared to Prior Year
• Net sales of $179.0 million compared to $227.0 million in the prior year, a decrease of 21.1%, primarily driven by a decline in prescription medication sales.
• Net loss of $57.3 million, or $(2.74) per diluted share, compared to a net loss of $6.3 million, or $(0.30) per diluted share in the prior year. The increase to net loss was primarily driven by a goodwill impairment charge of $26.7 million recorded in the first quarter of fiscal 2026, an increase in stock-based compensation expense, driven by the non-recurrence of an $8.7 million one-time non-cash stock compensation reversal associated with executive departures in the prior year, an increase in professional fees and executive severance costs, of which $4.5 million were one-time charges related to the whistleblower investigation, and lower gross profit resulting from decreased net sales. These factors were partially offset by a lower provision for income taxes, driven by the Company establishing a full valuation allowance against its net deferred tax asset in the prior year.
• Adjusted EBITDA was $(15.4) million compared to $0.7 million for the prior year.
“We are pleased to report a modest sequential quarterly increase in fourth quarter net sales, demonstrating positive momentum as we close out the year,” said Leslie Campbell, Interim Chief Executive Officer and President. “Throughout 2026, we focused on stabilizing our core business and strengthening the foundation for future long term value creation. We completed strategic, operational and technology initiatives that collectively reduced our cost structure and represent an important foundation for our future. We will continue to focus on operational excellence, driving sustainable long-term results, and delivering value for shareholders. We intend to do this in part through improved customer retention by leveraging our operational improvements, and also by expanding our market footprint through B2B relationships utilizing our membership programs as well as our white-label pharmacy fulfillment services like our recently announced Master Services Agreement with Rural King.”
In December 2025, the Company received two unsolicited, non-binding preliminary proposals from two separate third parties to acquire all of the outstanding shares of Common Stock of the Company at prices ranging from $4.00 to $4.25 per share in cash, subject to customary conditions, including the satisfactory completion of due diligence and the negotiation and execution of a mutually acceptable definitive agreement. In response to the receipt of these proposals, the Board of Directors of the Company (the "Board"), consistent with its fiduciary duties and in consultation with its financial and legal advisors, carefully evaluated the two unsolicited proposals and directed its financial advisor to actively solicit interest in a potential sale transaction from other strategic and financial sponsors that the Company and its financial advisor believed might have an interest in, and the financial capacity to consummate, a potential acquisition of the Company at a price and on terms that would maximize value for the Company's stockholders. Following this process and after careful deliberation and consideration of the alternatives reasonably available to the Company, the Board determined that it is in the best interests of the Company and its stockholders not to proceed with either of the publicly announced proposals, as a result of which the Company is continuing to operate as an independent, publicly traded company. However, the Board remains open to considering any inbound indications of interest with respect to a potential transaction that may be received in the future and will continue to act in accordance with its fiduciary duties to evaluate any such proposals should they arise.¹
Adjusted EBITDA is a non-GAAP financial measure. See “Non-GAAP Financial Measures” for additional information on non-GAAP financial measures and a reconciliation to the most comparable GAAP measures.
Earnings Webcast
A webcast discussing fourth quarter and fiscal 2026 results is available at the “News & Events” section of the Company’s investor relations website at https://investors.petmeds.com/News--Events/events-and-presentations/default.aspx.
About PetMed Express, Inc.... (truncated)pany offers a comprehensive range of pet health solutions - including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit www.PetMeds.com and www.PetCareRx.com
Forward Looking Statement
Financial statements
Income Statement
Three Months Ended March 31, — (In thousands, except for share and per share amounts) (Unaudited)
| Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 | Year Ended March 31, – 2026 | Year Ended March 31, – 2025 | ||
|---|---|---|---|---|---|
| Net sales | 42,817 | 50,760 | 179,021 | 226,972 | |
| Cost of sales | 28,875 | 35,564 | 126,679 | 157,835 | |
| Inventory write-down | 2,126 | ||||
| Gross profit | 13,942 | 15,196 | 50,216 | 69,137 | |
| Operating expenses: | General and administrative | 11,415 | 12,494 | 50,733 | 38,647 |
| Operating expenses: | Advertising | 5,792 | 5,448 | 21,511 | 23,781 |
| Operating expenses: | Depreciation and amortization | 2,427 | 2,074 | 9,387 | 7,039 |
| Operating expenses: | Impairment of goodwill and intangible assets | 1,200 | 27,258 | 1,200 | |
| Operating expenses: | Total operating expenses | 19,634 | 21,216 | 108,889 | 70,667 |
| Operating expenses: | Loss from operations | -5,692 | -6,020 | -58,673 | -1,530 |
| Other income: | Interest income (expense), net | 1,256 | -123 | 511 | 185 |
| Other income: | Other, net | 273 | 161 | 803 | 758 |
| Other income: | Total other income (expense) | 1,529 | 38 | 1,314 | 943 |
| Other income: | (Loss) income before provision for income taxes | -4,163 | -5,982 | -57,359 | -587 |
| Other income: | (Benefit) provision for income taxes | -102 | 5,662 | -73 | 5,684 |
| Other income: | Net loss | -4,061 | -11,644 | -57,286 | -6,271 |
| Net loss per common share: | Basic | -0.19 | -0.56 | -2.74 | -0.3 |
| Net loss per common share: | Diluted | -0.19 | -0.56 | -2.74 | -0.3 |
| Weighted average number of common shares outstanding: | Basic | 21,033,007 | 20,638,348 | 20,921,361 | 20,596,022 |
| Weighted average number of common shares outstanding: | Diluted | 21,033,007 | 20,638,348 | 20,921,361 | 20,596,022 |
Income Statement
Three Months Ended — PetMed Express, Inc. ($ in thousands, except percentages)
| Three Months Ended – March 31, 2026 – Consolidated Reconciliation of GAAP Net Loss to Adjusted EBITDA: | Three Months Ended – March 31, 2025 – Consolidated Reconciliation of GAAP Net Loss to Adjusted EBITDA: | $ Change – Consolidated Reconciliation of GAAP Net Loss to Adjusted EBITDA: | % Change – Consolidated Reconciliation of GAAP Net Loss to Adjusted EBITDA: | ||
|---|---|---|---|---|---|
| Net loss | -4,061 | -11,644 | 7,583 | -65.0% | |
| Add (subtract): | Share-based compensation expense | 272 | 593 | -321 | -54.0% |
| Add (subtract): | Income taxes | -102 | 5,662 | -5,764 | -102.0% |
| Add (subtract): | Depreciation and amortization | 2,427 | 2,074 | 353 | 17.0% |
| Add (subtract): | Interest expense (income), net | -1,256 | 123 | -1,379 | -1121.0% |
| Add (subtract): | Acquisition/Partnership transactions and other items | 26 | -26 | n/m | |
| Add (subtract): | Employee severance | 75 | -75 | n/m | |
| Add (subtract): | Professional fees (1) | -65 | -65 | n/m | |
| Add (subtract): | Impairment of goodwill and intangible assets | 1,200 | -1,200 | n/m | |
| Add (subtract): | Adjusted EBITDA | -2,785 | -1,891 | -894 | 47.0% |
Balance Sheet
(In thousands, except for share and per share amounts) (Unaudited)
| March 31, 2026 | March 31, 2025 | ||
|---|---|---|---|
| Current assets: | Cash and cash equivalents | 21,412 | 54,720 |
| Current assets: | Accounts receivable, less allowance for credit losses of $25 and $91, respectively | 1,908 | 2,317 |
| Current assets: | Inventories, net | 13,608 | 16,205 |
| Current assets: | Prepaid expenses and other current assets | 6,378 | 5,330 |
| Current assets: | Prepaid income taxes | 258 | 299 |
| Current assets: | Total current assets | 43,564 | 78,871 |
| Noncurrent assets: | Property and equipment, net | 26,326 | 28,859 |
| Noncurrent assets: | Intangible and other assets, net | 10,789 | 13,346 |
| Noncurrent assets: | Goodwill | 26,658 | |
| Noncurrent assets: | Operating lease right-of-use assets, net | 512 | 966 |
| Noncurrent assets: | Total noncurrent assets | 37,627 | 69,829 |
| Noncurrent assets: | Total assets | 81,191 | 148,700 |
| Current liabilities: | Accounts payable | 20,906 | 23,564 |
| Current liabilities: | Sales tax payable | 22,261 | 24,867 |
| Current liabilities: | Accrued expenses and other current liabilities | 7,665 | 11,711 |
| Current liabilities: | Current operating lease liabilities | 493 | 461 |
| Current liabilities: | Deferred revenue | 689 | 2,085 |
| Current liabilities: | Income taxes payable | 20 | 80 |
| Current liabilities: | Total current liabilities | 52,034 | 62,768 |
| Current liabilities: | Deferred tax liabilities, net | 175 | 263 |
| Current liabilities: | Long-term operating lease liabilities | 42 | 535 |
| Current liabilities: | Total liabilities | 52,251 | 63,566 |
| Preferred stock, $0.001 par value, 5,000,000 shares authorized: | Convertible Preferred stock, $0.001 par value, with a liquidation preference of $4 per share, 250,000 shares authorized; 2,500 and 2,500 convertible shares issued and outstanding, respectively | 9 | 9 |
| Preferred stock, $0.001 par value, 5,000,000 shares authorized: | Common stock, $.001 par value, 40,000,000 shares authorized; 21,385,638 and 20,656,822 shares issued and outstanding, respectively | 21 | 21 |
| Preferred stock, $0.001 par value, 5,000,000 shares authorized: | Additional paid-in capital | 19,647 | 18,560 |
| Preferred stock, $0.001 par value, 5,000,000 shares authorized: | Retained earnings | 9,263 | 66,544 |
| Preferred stock, $0.001 par value, 5,000,000 shares authorized: | Total shareholders' equity | 28,940 | 85,134 |
| Preferred stock, $0.001 par value, 5,000,000 shares authorized: | Total liabilities and shareholders' equity | 81,191 | 148,700 |
Cash Flow
Year Ended March 31, — (In thousands) (Unaudited) (in thousands)
| Year Ended March 31, – 2026 | Year Ended March 31, – 2025 | ||
|---|---|---|---|
| Cash flows from operating activities: | Net loss | -57,286 | -6,271 |
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | Depreciation and amortization | 9,387 | 7,039 |
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | Impairment of goodwill and intangible assets | 27,258 | 1,200 |
Full release
This press release may contain “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties, including the Company’s ability to meet the objectives included in its business plan. Important factors that could cause results to differ materially from those indicated by such forward-looking statements are set forth in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in the Company’s Annual Report on Form 10-K to be filed for the year ended March 31, 2026. The Company’s future results may also be impacted by other risk factors listed from time to time in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, the Company's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.
Investor Contact:
ICR, LLC
Reed Anderson
(646) 277-1260 investor@petmeds.com